{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:22:45Z","timestamp":1790140965862,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,3,23]]},"DOI":"10.1038\/s41416-022-02100-1","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:02:45Z","timestamp":1671217365000},"page":"886-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours"],"prefix":"10.1038","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-7616","authenticated-orcid":false,"given":"Yuto","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-4359","authenticated-orcid":false,"given":"Tomohide","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuto","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kanaseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Hirohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Emori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehide","family":"Nakatsugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Torigoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"2100_CR1","first-page":"669","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16:669.","journal-title":"Nat Rev Drug Discov"},{"key":"2100_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharm Ther. 2020;107:112\u201322.","journal-title":"Clin Pharm Ther"},{"key":"2100_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12254-021-00703-7","volume":"14","author":"\u00d6 Umut","year":"2021","unstructured":"Umut \u00d6, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. Memo. 2021;14:143\u20139.","journal-title":"Memo"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","volume":"20","author":"S Kakarla","year":"2014","unstructured":"Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J Sudbury Mass. 2014;20:151\u20135.","journal-title":"Cancer J Sudbury Mass"},{"key":"2100_CR5","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28:2320\u201339.","journal-title":"Mol Ther"},{"key":"2100_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/0008-5472.CAN-11-3062","volume":"72","author":"S Nishizawa","year":"2012","unstructured":"Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem\u2013like cells. Cancer Res. 2012;72:2844\u201354.","journal-title":"Cancer Res"},{"key":"2100_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/cas.12362","volume":"105","author":"R Morita","year":"2014","unstructured":"Morita R, Nishizawa S, Torigoe T, Takahashi A, Tamura Y, Tsukahara T, et al. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci. 2014;105:389\u201395.","journal-title":"Cancer Sci"},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s41416-020-1017-1","volume":"123","author":"H Tadano","year":"2020","unstructured":"Tadano H, Tsukahara T, Mizushima E, Akamatsu A, Watanabe K, Nojima I, et al. Development of an artificial antibody specific for HLA\/peptide complex derived from cancer stem-like cell\/cancer-initiating cell antigen DNAJB8. Br J Cancer. 2020;123:1387\u201394.","journal-title":"Br J Cancer"},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1182\/blood.V98.6.1872","volume":"98","author":"K Kuzushima","year":"2001","unstructured":"Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402\u2013restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 2001;98:1872\u201381.","journal-title":"Blood"},{"key":"2100_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00375376","volume":"21","author":"RD Salter","year":"1985","unstructured":"Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985;21:235\u201346.","journal-title":"Immunogenetics"},{"key":"2100_CR11","first-page":"2273","volume":"48","author":"T Wada","year":"1988","unstructured":"Wada T, Uede T, Ishii S, Matsuyama K, Yamawaki S, Kikuchi K. Monoclonal antibodies that detect different antigenic determinants of the same human osteosarcoma-associated antigen. Cancer Res. 1988;48:2273\u20139.","journal-title":"Cancer Res"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/sj.bjc.6605330","volume":"101","author":"M Murase","year":"2009","unstructured":"Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S, et al. Side population cells have the characteristics of cancer stem-like cells\/cancer-initiating cells in bone sarcomas. Br J Cancer. 2009;101:1425\u201332.","journal-title":"Br J Cancer"},{"key":"2100_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Leth\u00e9 B, Lehmann F, Van Baren N, Baurain JF, De Smet C, et al. Characterization of an antigen that Is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199\u2013208.","journal-title":"Immunity"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2326-6066.CIR-17-0518","volume":"6","author":"S Miyamoto","year":"2018","unstructured":"Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, et al. The antigen ASB4 on cancer stem cells serves as a target for CTL immunotherapy of colorectal cancer. Cancer Immunol Res. 2018;6:358\u201369.","journal-title":"Cancer Immunol Res"},{"key":"2100_CR15","first-page":"1731","volume":"8","author":"Y Hirohashi","year":"2002","unstructured":"Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8:1731\u20139.","journal-title":"Clin Cancer Res"},{"key":"2100_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ijc.10317","volume":"99","author":"CA Aarnoudse","year":"2002","unstructured":"Aarnoudse CA, Kr\u00fcse M, Konopitzky R, Brouwenstijn N, Schrier PI. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning. Int J Cancer. 2002;99:7\u201313.","journal-title":"Int J Cancer"},{"key":"2100_CR17","doi-asserted-by":"crossref","unstructured":"Sayers EW, Bolton EE, Brister JR, Canese K, Chan J, Comeau DC, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res.\u00a02022;50:D20\u20136.","DOI":"10.1093\/nar\/gkab1112"},{"key":"2100_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33:1688\u201396.","journal-title":"J Clin Oncol"},{"key":"2100_CR19","doi-asserted-by":"crossref","unstructured":"Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol. 2020;10:1000.","DOI":"10.3389\/fonc.2020.01000"},{"key":"2100_CR20","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma. Blood. 2011;118:6050\u20136.","journal-title":"Blood"},{"key":"2100_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"2100_CR22","doi-asserted-by":"publisher","first-page":"17225","DOI":"10.1074\/jbc.M112.421685","volume":"288","author":"J Gillis","year":"2013","unstructured":"Gillis J, Schipper-Krom S, Juenemann K, Gruber A, Coolen S, van den Nieuwendijk R, et al. The DNAJB6 and DNAJB8 protein chaperones prevent intracellular aggregation of polyglutamine peptides. J Biol Chem. 2013;288:17225\u201337.","journal-title":"J Biol Chem"},{"key":"2100_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molcel.2010.01.001","volume":"37","author":"J Hageman","year":"2010","unstructured":"Hageman J, Rujano MA, van Waarde MAWH, Kakkar V, Dirks RP, Govorukhina N, et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell. 2010;37:355\u201369.","journal-title":"Mol Cell"},{"key":"2100_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019\u201327.","journal-title":"Clin Cancer Res"},{"key":"2100_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"2100_CR26","doi-asserted-by":"publisher","first-page":"e0146501","DOI":"10.1371\/journal.pone.0146501","volume":"11","author":"M Yamashita","year":"2016","unstructured":"Yamashita M, Hirohashi Y, Torigoe T, Kusumoto H, Murai A, Imagawa T, et al. Dnajb8, a member of the heat shock protein 40 family has a role in the tumor initiation and resistance to docetaxel but Is dispensable for stress response. PLoS ONE. 2016;11:e0146501.","journal-title":"PLoS ONE"},{"key":"2100_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","volume":"12","author":"J Wei","year":"2019","unstructured":"Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol OncolJ Hematol Oncol. 2019;12:62.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2100_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/cas.13501","volume":"109","author":"H Kusumoto","year":"2018","unstructured":"Kusumoto H, Hirohashi Y, Nishizawa S, Yamashita M, Yasuda K, Murai A, et al. Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of heat shock factor 1. Cancer Sci. 2018;109:741\u201350.","journal-title":"Cancer Sci"},{"key":"2100_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492\u2013500.","journal-title":"Leukemia"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02100-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:07:17Z","timestamp":1677715637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02100-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,23]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02100-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed by the guidelines established by the Declaration of Helsinki and was approved by the Ethics Committee of Sapporo Medical University. Healthy donors provided informed consent for the use of their blood samples in our research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}